{"id":"traditional-triple-antihypertensive-treatment","brandName":"traditional triple antihypertensive treatment","genericName":"traditional triple antihypertensive treatment","companyId":"first-affiliated-hospital-of-chengdu-medical-college","companyName":"First Affiliated Hospital of Chengdu Medical College","phase":"phase_3","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"The traditional triple antihypertensive treatment, developed by the First Affiliated Hospital of Chengdu Medical College, is under investigation for resistant hypertension. Current trials focus on novel interventional techniques, including adrenal artery ablation and embolization, aiming to address uncontrolled hypertension. Despite no FDA label, the treatment shows promise in early-phase studies.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This combination typically includes agents from different drug classes (such as ACE inhibitors/ARBs, calcium channel blockers, and diuretics or beta-blockers) that work synergistically to lower blood pressure via distinct pathways: reducing renin-angiotensin system activity, blocking calcium influx in vascular smooth muscle, and promoting sodium/fluid excretion or reducing cardiac output. The multi-mechanism approach allows for more effective blood pressure control with potentially lower doses of individual agents.","oneSentence":"Traditional triple antihypertensive treatment combines three different classes of blood pressure-lowering agents to reduce systemic vascular resistance and blood pressure through complementary mechanisms.","_ai_confidence":"medium"},"administration":{},"safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Electrolyte abnormalities"},{"rate":null,"effect":"Cough (if ACE inhibitor component)"},{"rate":null,"effect":"Peripheral edema (if calcium channel blocker component)"}]},"trials":[],"indications":{"approved":[{"name":"Hypertension (resistant or difficult-to-control)"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}